Innovative Development from Discovery to Manufacturing

With over 40 successful commercial drug launches, IPS’ fully-integrated IND program is positioned to provide expert guidance every step of the way. From research and target identification to clinical trials and market launch, IPS’ comprehensive suite of customized services accelerates the drug discovery process, empowering organizations to bring novel therapeutics to market faster.

Scientific services are actively managed by seasoned industry specialists and designed to facilitate the identification of potential therapeutic compounds through targeted scientific approaches. Expert guidance throughout all phases of the drug development journey is designed to equip stakeholders with the critical insights required to make well-informed decisions.

Unlock the full potential of your pharmaceutical research with our Innovative Drug Discovery & Development Services.

The following manufacturing services are available for both Small Molecules and Biologics:

    • cGMP development and formulation services
    • APIs, NCEs, intermediates
    • Regulatory starting materials
    • Route scouting and scale-up
    • ICH Stability
    • Complete analytical capabilities
  • Discovery Chemistry and Biology
  • Lead and hit identification
  • Analog synthesis for lead optimization
  • Salt and Solid-State assessment
  • Scale-up for additional studies
  • Platform Technologies
  • Biodistribution
  • Toxicology
  • Efficacy Studies
  • ADME/DMPK
  • Safety assessment
  • Pharmacology
    • In-vitro
    • In-vivo
  • APIs, NCEs, Intermediates, Starting Materials
  • CMC Support
  • Process Optimization
  • Process Validation
  • In Process Controls Development
  • Scale up of Processes through Commercialization
  • Complete Analytical and Bio-analytical capabilities
  • Method Development and Validation
  • Impurity ID and Synthesis
  • Stability
  • Mammalian Cell Culture
  • Bacterial Cell Culture
  • Upstream and Downstream Optimization
  • Downstream processing of proteins
  • Macrolides and Peptide Synthesis
  • Therapeutic Antibodies
  • Conjugates
  • Proteins
  • Cytotoxics
  • Semi-synthetics and natural products
  • Extensive glove-box capabilities
  • From g to 100s of kg
  • Peptide and Protein Expression (multiple expression systems)
  • Peptides and Plasmids / Viral Vectors
  • mAb Development and Production
  • Vaccines and Virus-like Particles
  • Cell-based Therapies
  • Bacteriophage Services
    • Antibodies
      • Custom mAb, Fab and Fc Development
      • cGMP Production
      • 125L to 3000L cGMP capacity
    • Cytotoxic Payloads
      • Auristatins (MMAE, MMAF); Maytansinoids (DM1, DM4); Exatecan; Eribuline; Dolostatins; Calicheamicins; Duocarmycins; PBD dimers; α-Amanitin
      • Custom cytotoxics; natural products
      • OEB 5 & OEL < 1 μg/m3 Containment; up to multi-kg quantities; cGMP
    • Linkers
      • Cleavable & non-cleavable linkers
      • Hydrazones; Peptides; Disulfides; Pegylated; Thioethers; Carbohydrates
      • Linker development
      • PR&D and cGMP manufacturing
    • Bioconjugation & Sterile Fill Finish
      • Cleavable & non-cleavable linkers
      • Hydrazones; Peptides; Disulfides; Pegylated; Thioethers; Carbohydrates
      • Linker development
      • PR&D and cGMP manufacturing
    • Drug Product Manufacturing
      • Solids
      • Liquids
      • Parenterals
    • Pre-formulation activities
      • Particle size
      • Milling
      • Solubility
    • Solid Dispersions
    • Spray Drying
    • Hot Melt Extrusions
    • Liquid Dispersions
    • Targeted Liposomes
    • Liquid Coated Nanoparticles
    • Excipients; Cyclodextrins (Dexolve)
    • LNP Components – Lipids and carbohydrate chemistries
    • Sustained Release Coatings
    • Enteric Coatings
    • Lipid Coated Solids
    • Solubility / Bioavailability Enhancements
  • Assisted in over 40 commercial drug launches
  • 5 NDA filings in the past 5 years
  • Including key intermediates, drug substance and drug product
  • Assisting in staging early-stage assets to acquisition
  • Actively engaged in reducing costs and identifying multi-source strategies
  • cGMP development and formulation services
  • APIs, NCEs, intermediates, regulatory starting materials
  • Route scouting and scale-up
  • ICH Stability
  • Packaging
  • IND Enabling Toxicology (exploratory & GLP)
  • Genotoxicity (in vitro & in vivo)
  • Immunotoxicology
  • Developmental & Reproductive
  • Carcinogenesis
  • Chronic & Inhalation toxicology
  • Mouse to Non-human primates
  • FDA Inspected Sites